Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor Spine Metastases 1Sarcoma 1Rectal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Lymphoma, Follicular 1Locally Advanced Colon Cancer 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Anxiety Disorders 1Amenorrhea 1

Interventions

Radiotherapy 122Temozolomide 110Carboplatin 53Filgrastim 46Vincristine 43Etoposide 39Cyclophosphamide 37Chemotherapy, Adjuvant 37Cisplatin 36Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 24Lomustine 22Thiotepa 21Methotrexate 20Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Drug Therapy 13Topotecan 12Paclitaxel 12Ifosfamide 12Thalidomide 11Radiation 11sargramostim 10Specimen Handling 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Postoperative Period × Clear all
NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Terminated
10 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡